Finch Therapeutics Group earnings missed by 0.15, revenue fell short of estimates
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Under 61% of Finch Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Finch Therapeutics Group pink sheet suggests that many investors are alarmed at this time. Finch Therapeutics' investing sentiment shows overall attitude of investors towards Finch Therapeutics Group.
Finch |
Finch Therapeutics Group earnings missed by 0.15, revenue fell short of estimates
Read at investing.com
 |
Finch Therapeutics Fundamental Analysis
We analyze Finch Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Finch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Finch Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Finch Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Finch Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Finch Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics with similar companies.
Peers
Finch Therapeutics Related Equities
| KPRX | Kiora Pharmaceuticals | 1.03 | ||||
| CELC | Celcuity LLC | 0.91 | ||||
| RNXT | RenovoRx | 0.72 | ||||
| XLO | Xilio Development | 0.99 | ||||
| QNRX | Quoin Pharmaceuticals | 1.49 | ||||
| IKNA | Ikena Oncology | 3.01 | ||||
| HOWL | Werewolf Therapeutics | 4.32 | ||||
| EWTX | Edgewise Therapeutics | 4.37 | ||||
| LGVN | Longeveron LLC | 4.52 | ||||
| REVB | Revelation Biosciences | 4.69 | ||||
| GLUE | Monte Rosa | 5.22 | ||||
| CCCC | C4 Therapeutics | 5.62 | ||||
| DSGN | Design Therapeutics | 6.18 | ||||
| NTRB | Nutriband | 8.44 | ||||
| VRAX | Virax Biolabs | 10.93 | ||||
| STOK | Stoke Therapeutics | 15.52 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |